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ABSTRACT 16 
Metabolomic studies aimed to dissect the connection between the development of type 2 diabetes and 17 
obesity are still scarce. In the present study, fasting serum from sixty-four adult individuals classified 18 
into four sexmatched groups by their BMI [non-obese versus morbid obese] and the increased risk of 19 
developing diabetes [prediabetic insulin resistant state versus non-prediabetic non-insulin resistant] 20 
was analyzed by LC- and FIAESI- MS/MS–driven metabolomic approaches. Altered levels of 21 
[lyso]glycerophospholipids was the most specific metabolic trait associated to morbid obesity, 22 
particularly lysophosphatidylcholines acylated with margaric, oleic and linoleic acids [lysoPC C17:0: 23 
R = −0.56, p = 0.0003; lysoPC C18:1: R = −0.61, p = 0.0001; lysoPC C18:2 R = −0.64, p b 0.0001]. 24 
Several amino acidswere biomarkers of risk of diabetes onset associated to obesity. For instance, 25 
glutamate significantly associatedwith fasting insulin [R=0.5, p=0.0019] and HOMA-IR [R=0.46, 26 
p=0.0072],while glycine showed negative associations [fasting insulin: R = −0.51, p = 0.0017; 27 
HOMA-IR: R = −0.49, p = 0.0033], and the branched chain amino acid valine associated to 28 
prediabetes and insulin resistance in a BMI-independentmanner [fasting insulin: R=0.37, 29 
p=0.0479;HOMA-IR: R=0.37, p=0.0468].Minority sphingolipids including specific 30 
[dihydro]ceramides and sphingomyelins also associated with the prediabetic insulin resistant state, 31 
hence deserving attention as potential targets for early diagnosis or therapeutic intervention. 32 
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INTRODUCTION 51 
Metabolomics [1] is opening avenues to the discovery of biomarkers associatedwith insulin resistance 52 
and type 2 diabetes (T2D) [2–5].Most of the human large-scale population-based studies carried out 53 
so far, however, mirrored the strong epidemiologic relationship between obesity and the impairment 54 
of glycemic control, and no emphasiswas given to dissect the connection between obesity and 55 
diabetes or on the impact of the degree of adiposity in differentiating diabetic and nondiabetic 56 
individuals [6–10]. Hence, the identified metabolites of diabetes often coincide with obesity markers 57 
and not enable to corroborate the actual contribution of obesity in their predictive capacity. Moreover, 58 
since the establishment of T2D generally occurs in a later phase of the natural history of obesity [11], 59 
the identification of biomarkers of early diabetes onset prior to its clinical diagnosis is crucial to 60 
define the first metabolic derangements associated with incipient glycemic control impairment, and 61 
ultimately promote prediction, early diagnosis and intervention of the disease at earlier stages [12]. 62 
Even so, evidence indicates that individuals' risk of developing diabetes may not uniformly depend 63 
on their body size [13,14]. Obese population subsets who maintain blood sugar control parameters 64 
within the normal range do exist, even at evolved stages of obesity (Body Mass Index, BMI ≥ 40) 65 
[15], aswell as T2D occur among adult lean individuals [16]. Although the clinical relevance of these 66 
subgroups remains debated [17], the study of discordant metabolic phenotypes for obesity and 67 
diabetes provides a unique and poorly unexploited opportunity to examine the interrelations between 68 
adipose tissue expansion and the gradual development of T2D and its sequelae [disease risk 69 
assessment]. However, the studies focused on themare still very scarce, small-scaled [18–20] or not 70 
focused on humans [21]. In the present study, we propose that the metabolic profiling of human 71 
concordant and discordant phenotypes for obesity and prediabetes/ insulin resistancewould define 72 
themetabolic alterations associated to adipose tissue expansion fromthose related to the incipient 73 
failure in the glucose homeostasis, and help to dissect the connection between the two diseases. 74 
Univariate statistics was first applied to highlight any significant metabolic variation among the 75 
phenotypic groups in study. Age-adjusted regression analysis was used to assess the statistical 76 
significance of the relations of individual metabolites with the clinical traits of morbid obesity and 77 
prediabetes/insulin resistance, and the significant associationswere visualized into organicmetabolic 78 
networks. Finally, the diagnostic power of the most discriminant metabolites in correctly classifying 79 
the obese and prediabetic/insulin resistance phenotypes was evaluated. 80 
2. Material and Methods 81 
2.1. Subjects and Study Design 82 
Sixty-four adult individuals (19men and 45women)were recruited at the Virgen de la Victoria 83 
University Hospital and Carlos Haya Hospital (Málaga, Spain). Overall exclusion criteria were acute 84 
or chronic infection, a history of cancer, a history of alcohol abuse or drug dependence, and all type 85 
of antidiabetic, corticosteroid, or antibiotic drug treatments. Other treatments including anti-86 
inflammatory, antihypertensive and anti-cholesterolemic agents were recorded, but not restricted. 87 
The following measures were used for the clinical characterization of the subjects in study: a) 88 
anthropometric markers, measured by trained personnel using standardized techniques: body weight 89 
(kg), BMI (calculated as weight in kg/height2 in m2), waist circumference (cm), hip circumference 90 
(cm) and waist-hip index; b) markers of glucose regulation: plasma concentrations of fasting glucose 91 
(FG, mmol/L), fasting insulin (μU/mL), calculated Homeostatic Model Assessment (HOMA-IR 92 
index, arbitrary unit), glycated hemoglobin (HbA1c) concentration (%, mmol/mol), when available; 93 
c) blood pressure markers: diastolic and systolic blood pressure (mm Hg); d) blood lipid markers 94 
(mmol/L): total cholesterol, low-density lipoproteins and high-density lipoproteins cholesterol, and 95 
triglycerides. The individuals were then classified into four sex-matched phenotypic groups 96 
according to their BMI (non-obese if: BMI = 18,5–26,9 kg/m2;morbidly obese if: BMI N 40 kg/m2) 97 
and to the risk of developing type two diabetes based on fasting plasma glucose concentrations and 98 
insulin resistance (non-prediabetic/non-insulin resistant state if: FG b 100 mg/dL and HOMA-IR b 99 
2.5; prediabetic/insulin resistant state if: 100 ≤ FG b 126 mg/dL and HOMA-IR N 3.4). The cut-off 100 
of HOMA-IR for identifying insulin resistant individuals was obtained experimentally by dividing 101 
the entire initial cohort into quartiles, and revealed to be higher than that generally accepted as the 102 
clinical definition of insulin resistance (N2.60), in linewith previous reports [13]. The study protocol 103 
was approved by the local Ethics and Research Committees (Hospital Universitario Virgen de la 104 
Victoria,Málaga) and all participants provided written informed consent. 105 
2.2. Serum metabolomic profiling 106 
Fasting morning serum was stored at −80 °C until analysis. Metabolomic measurements were 107 
performed through two different platforms. A TSQ Vantage™ triple quadrupole mass spectrometer 108 
with ESI-II Ion Source (Thermo Scientific) equipped with a binary HPLC system was used for the 109 
in-house running of the AbsoluteIDQ p180 Kit (Biocrates Life Sciences AG, Innsbruck, Austria), 110 
through a standardized protocol as described bymanufacturer. Data acquisitionwas carried out using 111 
liquid chromatography tandem mass spectrometry (LC-MS/MS, 5 μL injection volume, ESI+, 112 
Thermo Scientific Hypersil GOLD 3.0 μm 2.1 × 100 mm HPLC column), and flow injection analysis 113 
tandem mass spectrometry (FIA-MS/MS, 10 μL injection volume, ESI+ and ESI-) techniques. The 114 
remaining lipid metabolites were quantitatively analyzed via a high-throughput flow injection ESI-115 
MS/MS screening method by Biocrates AG service (Innsbruck, Austria) through a validated protocol. 116 
Serum samples were analyzed in a randomized batch format, to avoid run-order effects. Quality 117 
control samples including three reference plasma spiked with increasing concentrations of the 118 
targeted metabolites (QC1, QC2, QC3) and zero samples (10 mM phosphate buffer with internal 119 
standards) were analyzed every 20 injections, throughout the whole run, to control the stability and 120 
performance of the system and evaluate the quality of the acquired data. Quantifications were 121 
achieved by multiple reaction monitoring, by reference to multipoint calibration curves and/or in 122 
combination with the use of stable isotope- labelled and other internal standards, to compensate for 123 
matrix effects, as previously described [22]. Data evaluation and quantitative data analysis was 124 
performed with MetIDQ™ software (Biocrates Life Sciences AG) enabling isotopic correction and 125 
basic statistical analysis. Validated analytical methods were applied, in conformance with FDA 126 
Guidelines (U.S. Department of Health and Human Services 2001), as described by the manufacturer 127 
(UM-P180-THERMO-3). 128 
2.3. Statistical analysis 129 
Statistical analyseswere performed in the R environment (R version 3.1.2). After excluding those 130 
metabolic measures below the limits of detection in N25% subjects in any of the phenotypic groups, 131 
and with high analytical variance in the QC2 replicates (CV N 25%), 246 successful metabolites 132 
remained for further analysis (Supplementary Table 1). Metabolite levels were log-transformed and 133 
Pareto scaled, missing values were imputed using nearest neighbor averaging (k=10) and the potential 134 
effects of age and drug intake on themetabolomics data was removed by the application of a feature 135 
selector on each dependent variable, according to the Akaike Information Criterion [23]. Univariate 136 
statisticswas first applied to highlight any significant variation among all the four phenotypic groups 137 
in study, and between the morbid obese and prediabetic/insulin resistance phenotypes (ANOVA and 138 
HSD Tukey contrasts for pairwise mean comparisons, p = 0.05, q = 0.05). Age-adjusted regression 139 
analysis was used to assess the statistical significance of the relations of individual metabolites with 140 
the clinical traits of obesity (BMI) and prediabetes/insulin resistance (fasting glucose concentrations, 141 
HOMA-IR). The significant metabolite-metabolite and metabolite-clinical correlations were 142 
visualized into an organic metabolic network (Cytoscape 3.3.0), where nodes represent metabolites 143 
while edges configure any positive or negative significant relation among them. Significance 144 
(adjusted p-value b0.05) and correlation degree cut-offs were set (adjusted Spearman's partial 145 
correlation coefficients N |0.35|) similarly to previous studies [24]. Finally,we evaluated the capacity 146 
to correctly classify the subjects in their phenotypic groups by using their metabolic profiling, without 147 
the help of clinical predictors, and compared the diagnostic power of the metabolic profiling with that 148 
of the clinical measures available. To do that, the most robust metabolic markers were first selected 149 
by features selection techniques, so to generate a consensus list of successfulmetabolic classifiers, 150 
and their diagnostic power was evaluated by applying linear and non-linear classification techniques 151 
(Supplementary material). 152 
3. Results 153 
Clinical baseline characteristics of the study subjects are shown in Table 1. Female participants were 154 
prevalent, but no gender-dependent differences were detected among groups (Chi-squared test, p = 155 
0.324). Table 2 summarizes the serumconcentrations of themetabolites which significantly 156 
differedamong the phenotypic groups. Although the current lack of established reference values for 157 
most of the metabolic species analyzed (i.e. lipid molecules), the concentration range (nM to μM) 158 
was in line with previous quantifications [25]. On the basis of their partial correlations, the measured 159 
metabolites allowed to depict a metabolic network (Fig. 1). Metabolites clearly clustered based on 160 
their biochemical classes and pathways membership, and phospholipids made the biggest cluster in 161 
the network, followed by amino acids and biogenic amines, ceramides and acylcarnitines sub-162 
networks. The associations of obesity and glycemic impairment with specific metabolites of the 163 
serum metabolic network are shown in Fig. 2. The strongest clinical-metabolite associations were 164 
observed between obesity markers and individual lyso- and glycerophospholipid species. More 165 
specifically, the levels of three lysophosphatidylcholines (lysoPC) showed very strong inverse 166 
relations with BMI (lysoPC C17:0: R=−0.56, p=0.0003; lysoPC C18:1: R=−0.61, p = 0.0001; lysoPC 167 
C18:2 R = −0.64, p b 0.0001), as well as with body weight, waist and hip circumference. Similar but 168 
less significant correlationswere also observed between obesity markers and serum phospholipids, 169 
especially diacyl- and alkyl acyl species with long-chain polyunsaturated fatty acids (PUFA). The 170 
circulating levels of glutamate and glycine levels associated weaklywith adipositymarkers but 171 
stronglywith insulin resistance, suggesting to be in the cross-talk between the two pathologies. 172 
Glutamate levels particularly showed positive associations with fasting insulin (R = 0.5, p = 0.0019) 173 
and HOMA-IR index (R = 0.46, p = 0.0072), while glycine concentrations negatively associated with 174 
the same parameters (fasting insulin: R = −0.51, p = 0.0017; HOMA-IR: R=−0.49, p=0.0033) 175 
(Supplementary Fig. 1). A positive association between the levels of the branched-chain amino acid 176 
(BCAA) valine and the degree of insulin resistance was also observed (fasting insulin: R= 0.37, 177 
p=0.0479;HOMA-IR: R=0.37, p=0.0468), independently from the BMI (Supplementary Fig. 1). 178 
Finally, the prediabetic and insulin resistant state confirmedmodest but positive correlationswith 179 
circulating nonpolar sphingolipids including several specific (dihydro)ceramides (increase of 180 
ceramide d18:1/C18:0 and dehydroceramides d18:0/ C18:0 and d18:0/C22:0) and sphingomyelins 181 
(increase of sphingomyelin C18:0). Metabolic versus clinical predictors. Both choline and 182 
ethanolaminecontaining lysolipids acylated with margaric acid (C17:0) oleic acid (C18:1) and 183 
linoleic acid (C18:2) were the best classifiers for morbid obesity, together with diacyl and acyl alkyl 184 
phosphocholines with very long-chain fatty acids (Supplementary Fig. 2). The amino acid valine 185 
confirmed to be within the selective markers of prediabetes, together with sphingomyelins C18:0 and 186 
C18:1. In contrast, alterations in the circulating levels of the amino acid glycine and different 187 
ceramide species were selected as metabolic classifiers of both conditions (e.g. hydroxyceramide 188 
C17:0, dihydroceramides C20:0, C22:0 and 24:1). The robustness of the top-ranked metabolic 189 
markers in correctly classifying the individuals on the basis of the obese and prediabetic phenotypes 190 
was poor in respect to the use of clinical predictors (53 to 56% error in predicting classification), 191 
(Supplementary Table 2) reasonably due to the difficulty in clearly defining themetabolic profile of 192 
an incipient glycemic impairment. When considering obesity and prediabetes for separate, in turn, 193 
prediction capacity improved notably, especially for the morbid obesity phenotype Table 3. 194 
4. Discussion 195 
The use of organic metabolic networks based on age-adjusted regression analysis was helpful in 196 
identifying significant associations of individual metabolites with prediabetes or insulin resistance 197 
and morbid obesity. 198 
4.1. Early metabolic markers associated to increased risk of diabetes development 199 
4.1.1. Variation in the amino acid profile 200 
Although the objective difficulty in defining themetabolic signature of an incipient glycemic 201 
impairment, compared to the characterization of an evolved state of obesity, altered levels of specific 202 
amino acids were detected in prediabetic patients, compared to non-prediabetic individuals, so to be 203 
proposed as suitable early predictors of increased risk for diabetes. Glutamate and glycine were the 204 
most significantly altered amino acids associated to the prediabetic phenotype (i.e. rise of glutamate 205 
versus progressive decline of glycine compared with the matched control group), followed by the 206 
BCAA valine. Their circulating levels also associated with adiposity markers [namely BMI, body 207 
weight and waist circumference], but in a modest extent. In morbidly obese subjects, for instance, a 208 
2-fold increase in the serumlevels of glutamatewas particularly observed, compared to non-209 
prediabetic obese controls, suggesting alterations in the glutamatemetabolismas a 210 
selectivemetabolicmarker of an early onset of diabetes in subjectswith high BMI. By its conversion 211 
to α-ketoglutarate, a precursor of glutamine, higher concentrations of glutamatemight provide an 212 
alternative energy source to either glucose via glycolysis or fatty acids via β-oxidation [26], thus 213 
possibly playing a compensatory role against glucose and lipid metabolism impairment. Hence 214 
reciprocal associations of glutamine and glutamate circulating levels with glycemic impairment might 215 
reflect the role of glutamate as a substrate of the tricarboxylic acid cycle. In linewith these 216 
speculations, in our study glutamine levels decreased progressively across themorbid obese, 217 
prediabetic and morbid prediabetic/obese individuals, although differences did not reached the 218 
statistical significance. A strong correlation between insulin resistance and the fasting glutamate has 219 
been described in large population-based studies [27], and decreased levels of glycine have been 220 
proposed as an early predictor of incident dysglicaemia and insulin resistance in high-risk nondiabetic 221 
subjects in follow-up studies [8,9]. Although any causative relations between altered levels of 222 
glutamate or glycine and metabolic impairment have been proved so far [28], the circulating 223 
concentrations of bothmetabolites have been shown to drastically reverse to the normal concentration 224 
range after gastric bypass surgery or behaviouralweight loss and to predict the concomitant 225 
improvement of glycemic control [29,30], thus reinforcing the possible mechanistic relation with the 226 
beneficial metabolic adaptations associated to weight loss. It is noteworthy that a low-grade 227 
inflammatory state is considered as one of the fundamentalmechanisms in the progression of obesity-228 
related diseases [31]. Interestingly, inflammation has been also proposed as an intriguing intersection 229 
between the metabolism of the amino acids significantly altered in our study and the development of 230 
prediabetes. For instance, in vivo studies have suggested that glycine might suppress the production 231 
of pro-inflammatory cytokines (i.e. TNF-α and IL-6), increase adiponectin secretion through the 232 
activation of PPAR-γ, and prevent insulin resistance and associated inflammatory diseases [32]. The 233 
effects of inflammatory cytokines on glutamate metabolismare also under investigation. In the 234 
scenario, the progressive alteration of glutamate and glycine levels from the lean to the ‘healthy’ 235 
morbid obese up to the morbid prediabetic obese phenotype, observed in our study, may confirm a 236 
link between the metabolism of these amino acids and a lower inflammatory state. Finally, in our 237 
study the association of BCAA valinewith insulin resistance was BMI-independent, and do not 238 
confirm a primary association between altered BCAA levels and obesity. The implication of an 239 
impaired BCAA metabolism in the development and interconnection of obesity and diabetes is 240 
currently a prominent topic of discussion [33]. In line with our findings, elevated blood 241 
concentrations of BCAA and their derivatives has been observed as an early manifestation of insulin 242 
resistance and diabetes [reviewed in [34]]. A significant correlation between plasma valine 243 
concentration and HOMA index has been also demonstrated in subjects spanning normal glucose 244 
tolerance, impaired glucose tolerance, and diabetes [35], and similar results were obtained adjusting 245 
plasma BCAA levels for BMI [2,36] or waist circumference [37]. However, several experimental 246 
studies also suggest that increased circulating BCAA would specifically mirror obesity-dependent 247 
diabetic states, possibly related to altered adipose tissue BCAA catabolism [18, 38–40]. Although 248 
attempts to reconcile these disparate perspectives have been already proposed [41], more 249 
investigations are required to reach a definitive overview. 250 
4.1.2. Increase of circulating sphingolipids 251 
A substantive literature has accumulated implicating sphingolipids, especially enhanced ceramide 252 
generation, as mediators of diabetes and insulin resistance progression [42–44]. Besides confirming 253 
ceramides as an attractive therapeutic target for obesity-associated insulin resistance, our study 254 
specifically focused the attention on individual sphingolipid species significantly associated with the 255 
prediabetic phenotype, including sphingomyelin species with saturated acyl chains [i.e. 256 
sphingomyelin C18:0], ceramide d18:1/C18:0 and dihydroceramides d18:0/C18:0 and d18:0/C22:0. 257 
These last observations particularly sustain the concept that dihydroceramides are not merely inert 258 
precursors of ceramides, andwould confirma link between the accumulation of dihydroceramides and 259 
the changes in the dihydroceramide/ceramide ratio with the impairment of adipose tissue expansion 260 
and adipocyte function, through the alteration of membrane-associated processes [45]. Our findings 261 
would be also in line with an increased expression of the CerS1, the most abundant (dihydro)ceramide 262 
synthase isoform in skeletal muscle and specifically involved in the synthesis of C18:0 ceramides 263 
[44], recently described in mice fed a high-fat diet and associated with alterations in ceramide levels 264 
and glucose tolerance [46]. 265 
4.2. Morbid obese markers 266 
4.2.1. Drop of glycerophospholipids 267 
Recent large-scale metabolomic studies indicated several cholinecontaining [lyso]lipids, including 268 
lysoPC C18:2, as potential biomarkers of diabetes [7], and lysoPC C18:2 and glycine were confirmed 269 
to be predictive markers of diabetes in a second large-scale population-based (KORA) cohort [9]. In 270 
these works, however, no emphasis was given to the different degree of adiposity observed between 271 
diabetic and nondiabetic individuals (i.e. cases of diabetes often having higher BMI and waist 272 
circumference compared to the non-cases), thus not enabling to corroborate the actual contribution 273 
of obesity in the predictivity of these metabolic markers. In contrast, in our study, a significant drop 274 
of lyso- and glycerophospholipids clearly characterized the morbidly obese phenotype, independently 275 
fromthe glycemic state of the individuals. This would suggest that alterations of the (lyso)lipid 276 
metabolism would associate with adipose tissue expansion but not play a pivotal early role in the 277 
early onset on glycemic impairment, as also recently suggested [47]. The levels of three lysolipids, 278 
namely lysophosphocholines acylated with margaric acid (lysoPC C17:0) oleic acid (lysoPC C18:1) 279 
and linoleic acid (lysoPC C18:2), were particularly reduced inmorbid obesity. Thesemetabolic 280 
intermediates are enzymatically produced during the de−/re-acylation cycles that control the overall 281 
lipid species composition, and are considered a readout of β-oxidation. Despite their relatively short 282 
half-life, circulating lysoPC C18:1 and C18:2 have been previously described as independent 283 
correlates of glucose intolerance and insulin resistance in nondiabetic subjects, besides as putative 284 
lipid-signalling molecules [8,48]. In addition to lysolipids, in our study as in previous research, the 285 
vast majority of the diacyl glycerophospholipids which markedly decreased in serum of morbidly 286 
obese individuals were plasmalogens, namely phospholipids inwhich one of the two carbon atoms on 287 
glycerol is bonded to an alkyl chain via an ether linkage, as opposed to the usual ester linkage. In the 288 
compresence of severe obesity and impaired glycemic control, plasmalogens concentrations dropped 289 
even more (Table 2). On overall, significant plasmalogens consisted in long-chain and very longchain 290 
PUFA-containing phosphatidylcholines and phosphatidylethanolamines, thus probably mirroring 291 
enhanced fatty acid desaturation and elongation activities. A correlation between desaturase enzyme 292 
activities and obesity has been also found in several cases [49] and partly explained as a mechanism 293 
for modulating packing and degree of order in the membrane phospholipid bilayer. Lipidomic studies 294 
on twins discordant for body size (lean vs obese) recently suggested that individuals in the early stage 295 
of obesity had increased proportions of very longchain PUFA-containing phospholipids in their 296 
adipose tissue (despite their lower dietary intake of PUFA compared to the lean twins) and a 297 
proportional diminishment of phospholipids containing shorter and more saturated fatty acids, 298 
regulated by Elovl6 [49].With adipose cell expansion, more phospholipids have to be incorporated 299 
into the cellular membranes. Increasing PUFA content, decreasing plasmalogen concentration and 300 
using choline instead of ethanolamine-containing headgroup are known compensatory mechanisms 301 
of cell membranes to maintain fluidity, permeability to small molecules at the price, however, of 302 
increasing their vulnerability to inflammation. Although focused on the blood compartment and 303 
apparently conflicting, our data are consistent with the findings recently obtained at the adipose tissue 304 
level, since a down-regulation of plasmalogens in serumof obese twins was previously documented 305 
[50]. Certainly, an in-depth analysis of the adipose tissue membrane composition at different stages 306 
of obesity and metabolic impairment will be highly hoped to verify the hypothesis. Furthermore, it 307 
should be verified whether the circulating glycerophospholipid pool may mirror accumulation and 308 
structural functioning in adipose tissue. 309 
5. Conclusions 310 
Our targeted metabolomics approach gave a granular metabolic footprint of morbid obesity and 311 
prediabetes/insulin resistance. The alteration in the (lyso)phospholipid metabolism was the most 312 
specific trait associated tomorbid obesity, particularly mirrored by the circulating levels of lysoPC 313 
C17:0, C18:1 and C18:2. Results also indicate glutamate and glycine as biomarkers of early diabetes 314 
onset associated to obesity, while the association of valine with glycemic impairment was BMI-315 
independent, hence a primary association between altered branched-chain amino acids levels and 316 
obesity was not confirmed. In addition, minority sphingolipids including specific (dihydro)ceramides 317 
and sphingomyelins also associated with the prediabetic state, hence deserving attention as potential 318 
targets for early diagnosis or therapeutic intervention. The degree of redundancy in the fatty acyl 319 
composition observed across the altered lipid species should deserve attention in future studies (e.g. 320 
acylation with non-essential C18:0, C18:1, and essential C18:2n-6 fatty acids was the most common 321 
alteration associated to morbid obesity) since suggesting a specific association between their 322 
dysfunctional metabolism and the extreme adipose tissue expansion. So far, the mechanistic 323 
explanation is not so intuitive. Certainly, the interpretation of our data needs to be assessed within 324 
the context of the limitations of the presentwork. For instance, it iswell recognized that insulin 325 
resistance develops on a continuum, thus the use of cutting points of fasting glucose and insulin 326 
sensitivity to differentiate phenotypes at high versus low insulin sensitivity could be questionable. As 327 
well as, the spectrum of insulin sensitivity in the study cohort was not based on load testing such as 328 
the hyperinsulinemic euglycemic clamp and oral glucose tolerance test. Nevertheless, for this reason 329 
we experimentally calculated the HOMA-IR cut-off for identifying insulin resistant individuals, and 330 
set it at a higher value than usually accepted. Since the lack of significance among phenotypic 331 
categories should be interpreted in the context of sample size/statistical power, future researchwill 332 
require larger studies to confirm the predictively of the detected biomarkers in the case of subclinical 333 
glycemic impairment in apparently insulin sensitive and glucose tolerant obese subjects. Finally, the 334 
authors support large-scale studies to replicate and validate the results, as well as future studies 335 
focused on the study of pathways involved. 336 
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